IS5257A - Substitutive pyrazole which inhibits p38 kinase - Google Patents

Substitutive pyrazole which inhibits p38 kinase

Info

Publication number
IS5257A
IS5257A IS5257A IS5257A IS5257A IS 5257 A IS5257 A IS 5257A IS 5257 A IS5257 A IS 5257A IS 5257 A IS5257 A IS 5257A IS 5257 A IS5257 A IS 5257A
Authority
IS
Iceland
Prior art keywords
substitutive
pyrazole
kinase
inhibits
substitutive pyrazole
Prior art date
Application number
IS5257A
Other languages
Icelandic (is)
Inventor
Anantanarayan Ashok
Clare Michael
W. Collins Paul
Zuowu Crich Joyce
Devraj Rajesh
L. Flynn Daniel
Geng Lifeng
J. Hanson Gunnar
J. Koszyk Francis
Liao Shuyuan
A. Partis Richard
N. Rao Shashidar
Raj Selness Shaun
S. South Michael
A. Stealey Michael
M. Weier Richard
Xu Xiangdong
K. Khanna Ish
Original Assignee
G.D. Searle & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.D. Searle & Co. filed Critical G.D. Searle & Co.
Publication of IS5257A publication Critical patent/IS5257A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS5257A 1997-05-22 1999-11-19 Substitutive pyrazole which inhibits p38 kinase IS5257A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22
PCT/US1998/010436 WO1998052940A1 (en) 1997-05-22 1998-05-22 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
IS5257A true IS5257A (en) 1999-11-19

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5257A IS5257A (en) 1997-05-22 1999-11-19 Substitutive pyrazole which inhibits p38 kinase

Country Status (24)

Country Link
EP (1) EP1000055A1 (en)
JP (1) JP2002508754A (en)
KR (1) KR20010012854A (en)
CN (1) CN1264377A (en)
AP (1) AP1246A (en)
AU (1) AU754830C (en)
BG (1) BG64313B1 (en)
BR (1) BR9809147A (en)
CA (1) CA2291115A1 (en)
EA (1) EA003925B1 (en)
EE (1) EE9900527A (en)
GE (1) GEP20033053B (en)
HU (1) HUP0001880A3 (en)
ID (1) ID22982A (en)
IL (1) IL132991A (en)
IS (1) IS5257A (en)
NO (1) NO995695L (en)
NZ (1) NZ501112A (en)
OA (1) OA12981A (en)
PL (1) PL337020A1 (en)
SK (1) SK157899A3 (en)
TR (1) TR200000235T2 (en)
WO (1) WO1998052940A1 (en)
ZA (1) ZA984358B (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (en) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JP2002502380A (en) 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CA2346665A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
ES2188280T3 (en) 1998-12-16 2003-06-16 Aventis Pharma Ltd ACETALES HETEROARIL-CICLICOS.
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
ES2244231T3 (en) * 1998-12-25 2005-12-01 Teikoku Hormone Mfg. Co., Ltd. DERIVATIVES OF AMINOPIRAZOL.
ES2345921T3 (en) 1999-03-26 2010-10-06 Euro-Celtique S.A. PIRAZOLES, IMIDAZOLES, OXAZOLES, TIAZOLES AND PIRROLES REPLACED WITH ARILO AND ITS USE.
AU766079B2 (en) 1999-06-03 2003-10-09 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
HK1045507A1 (en) * 1999-08-12 2002-11-29 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AU7922100A (en) * 1999-10-25 2001-05-08 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles as the active agents and use of said compositions as plant protection agents with a fungicidal action
DE19952147A1 (en) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
JP2003528043A (en) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
US7053099B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
WO2001038314A1 (en) 1999-11-23 2001-05-31 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PT1309592E (en) 2000-08-14 2006-07-31 Ortho Mcneil Pharm Inc SUBSTITUTED PYRAZOLES
EP1364949A4 (en) * 2001-02-02 2005-11-23 Takeda Pharmaceutical INHIBITOR OF JNK
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
JP4310109B2 (en) 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Nitrogen-containing fused ring compound having pyrazolyl group as substituent and pharmaceutical composition thereof
HRP20030961B1 (en) 2001-05-24 2012-01-31 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
RU2277534C2 (en) * 2001-09-25 2006-06-10 Фармация Корпорейшн Method for preparing substituted pyrazoles
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
MXPA04002855A (en) 2001-09-25 2004-07-05 Pharmacia Corp Process for making substituted pyrazoles.
WO2003104223A1 (en) * 2002-06-05 2003-12-18 Pharmacia Corporation Pyrazole-derivatives as p38 kinase inhibitors
WO2004004725A2 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003268155A1 (en) * 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
PL377848A1 (en) 2003-02-07 2006-02-20 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
DE602005010714D1 (en) 2004-08-12 2008-12-11 Pfizer THE P38 MAP KINASE
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
ATE538118T1 (en) 2004-12-28 2012-01-15 Aska Pharm Co Ltd PYRIMIDINYLISOXAZOLE DERIVATIVE
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
US20090192164A1 (en) 2006-06-28 2009-07-30 Aska Pharmaceutical Co., Ltd. Treating agent of inflammatory bowel disease
ES2396251T3 (en) 2006-06-28 2013-02-20 Aska Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
JP4588791B2 (en) 2007-02-16 2010-12-01 あすか製薬株式会社 Pharmaceutical composition comprising a particulate oily suspension
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US20100144756A1 (en) * 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
EP2220048B1 (en) 2007-11-16 2017-01-25 Boehringer Ingelheim International GmbH Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CL2009000904A1 (en) 2008-04-21 2010-04-30 Shionogi & Co Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
WO2009138386A2 (en) 2008-05-13 2009-11-19 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
PL2324008T3 (en) 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylpyrazoles as protein kinase inhibitors
US8609690B2 (en) * 2008-08-25 2013-12-17 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
JP2012506388A (en) * 2008-10-23 2012-03-15 ロンザ リミテッド Method for the synthesis of substituted pyrazoles
MX2011005221A (en) * 2008-11-21 2011-08-03 Raqualia Pharma Inc Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity.
JP5670440B2 (en) 2009-06-02 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cyclic inhibitor of 11β-hydroxysteroid dehydrogenase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
AU2010288534A1 (en) * 2009-08-26 2012-03-15 Novartis Ag Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators
AR077975A1 (en) 2009-08-28 2011-10-05 Irm Llc PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
BR112012018358A2 (en) 2009-12-21 2016-08-09 Bayer Cropscience Ag tienylpiri (mi) dinilazole and its use to control phytopathogenic fungi
CN104958294A (en) 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 Sulfonamido derivatives of 3, 4-diarylpyrazoles as protein kinase inhibitors
AR081810A1 (en) 2010-04-07 2012-10-24 Bayer Cropscience Ag BICYCLE PIRIDINYL PIRAZOLS
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5938038B2 (en) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ Derivatives of pyrazolophenyl-benzenesulfonamide compounds and their use as antitumor agents
HUE032405T2 (en) * 2010-12-20 2017-09-28 Pfizer Novel fused pyridine compounds as casein kinase inhibitors
WO2012175513A1 (en) 2011-06-20 2012-12-27 Bayer Intellectual Property Gmbh Thienylpyri(mi)dinylpyrazole
JP2014524438A (en) 2011-08-17 2014-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Indenopyridine derivatives
UA114490C2 (en) 2011-10-06 2017-06-26 Байєр Інтеллектуал Проперті Гмбх Heterocyclylpyri(mi)dinylpyrazole as fungicidals
JP6211522B2 (en) 2011-10-06 2017-10-11 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Heterocyclylpyri (mi) dinylpyrazole
DE102011115525A1 (en) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Two-part bottle packaging device for containing pharmaceutical tablets or capsules, has bottle body and bottle base, where bottle is closed with pressure lock or with pressure lock injected at bottle body or with separate rotary lock
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
WO2013078264A1 (en) 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
AU2014236719B2 (en) 2013-03-15 2018-06-21 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
US9573904B2 (en) * 2013-12-12 2017-02-21 Sumitomo Chemical Company, Limited Aromatic compound and use thereof
CN104829536B (en) * 2015-05-04 2017-12-29 陕西科技大学 A kind of Phenylpyrazole carboxylic acid compound and its synthetic method for having antitumor activity
US10858314B2 (en) * 2015-05-27 2020-12-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CN109748873B (en) * 2017-11-08 2021-02-02 北京嘉林药业股份有限公司 Compounds and their use in the treatment of cancer
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THEREOF
WO2020124397A1 (en) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
EP3978487A1 (en) * 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
WO2022146698A1 (en) * 2020-12-29 2022-07-07 Revolution Medicines, Inc. Sos1 inhibitors and uses thereof
WO2025231152A1 (en) * 2024-04-30 2025-11-06 The Cleveland Clinic Foundation Compounds and methods for restoring beta-adrenergic receptor function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2753659B2 (en) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 Pyrazole derivatives
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JP3734180B2 (en) * 1994-12-28 2006-01-11 エーザイ株式会社 New pyrazole derivatives

Also Published As

Publication number Publication date
NO995695D0 (en) 1999-11-19
KR20010012854A (en) 2001-02-26
EA199900953A1 (en) 2000-10-30
ID22982A (en) 1999-12-23
PL337020A1 (en) 2000-07-31
WO1998052940A1 (en) 1998-11-26
AP9901715A0 (en) 1999-12-31
TR200000235T2 (en) 2000-05-22
BG103964A (en) 2000-08-31
NO995695L (en) 2000-01-21
AP1246A (en) 2004-02-07
SK157899A3 (en) 2000-08-14
AU754830B2 (en) 2002-11-28
AU7588398A (en) 1998-12-11
BG64313B1 (en) 2004-09-30
CA2291115A1 (en) 1998-11-26
EE9900527A (en) 2000-06-15
IL132991A0 (en) 2001-03-19
HUP0001880A3 (en) 2002-03-28
OA12981A (en) 2006-10-13
JP2002508754A (en) 2002-03-19
BR9809147A (en) 2000-08-01
ZA984358B (en) 1999-05-24
GEP20033053B (en) 2003-08-25
EP1000055A1 (en) 2000-05-17
HUP0001880A2 (en) 2001-03-28
NZ501112A (en) 2002-10-25
EA003925B1 (en) 2003-10-30
CN1264377A (en) 2000-08-23
AU754830C (en) 2004-02-12
IL132991A (en) 2005-11-20

Similar Documents

Publication Publication Date Title
IS5938A (en) Substituted pyrazole which inhibits P38 kinase
IS6298A (en) Teridinone which inhibits kinase
HUP0001880A3 (en) Substituted pyrazoles as p38 kinase inhibitors
NO20001907D0 (en) pyrazole
NO20002121D0 (en) Benzothiazol-protein-tyrosine kinase inhibitors
IS5069A (en) Nitrogen substituents with nitrogen inhibiting p38 protein kinase
NO995635L (en) 3 (5) heteroaryl-substituted pyrazoles as p38 kinase inhibitors
IS4939A (en) Bicyclic heteroaromatic compounds that inhibit protein tyrosine kinase
IS4936A (en) Bicyclic heteroaromatic compounds that inhibit protein tyrosine kinase
IS6326A (en) Tyrosine kinase inhibits
DE69830089D1 (en) Multilevel memory
NO20003154D0 (en) Insert the plug
DE69918223D1 (en) Component feeder
DK1089964T3 (en) hydrazine
ITMI992109A0 (en) GRAFT
EP1135135A4 (en) Chk1 kinase inhibitors
DK0967869T3 (en) fungicidal
GB9803399D0 (en) Protein kinase c
DE69719304D1 (en) component feeders
EE9800165A (en) Enhanced LHRH antagonists
DK1133471T3 (en) hydrazine
GB0023243D0 (en) Protein kinase regulation
PT986382E (en) Raf kinase inhibitors
IT1302498B1 (en) MODULAR TRUNK
UA2154S (en) UNIFORM SUIT FROM SEMI-WOOL FABRIC